Document is current
Any future updates will be listed below
-
Authors
Lafon, Thomas https://orcid.org/0000-0003-4424-8107
Cazalis, Marie-Angélique
Hart, Kimberly W.
Hennessy, Cassandra
Tazarourte, Karim
Self, Wesley H.
Akhavan, Arvin Radfar
Laribi, Saïd
Viglino, Damien
Douplat, Marion
Ginde, Adit A.
Tolou, Sophie
Mahler, Simon A.
Le Borgne, Pierrick
Claessens, Yann-Erick
Yordanov, Youri
Le Bastard, Quentin
Pancher, Agathe
Ducharme, Jim
Lindsell, Christopher J.
Shapiro, Nathan I.
-
Funding
Funding for this research was provided by:
bioMérieux
- License Information
-
More Information
Article History
Received: 8 April 2024
Accepted: 21 October 2024
First Online: 30 October 2024
Declarations
:
: TL, MAC, JD, YY, CJL, and NIS were part of the Steering committee of the study. MAC was a bioMerieux’s employee. MAC is a coinventor in patent applications covering the following markers: sVEGFR2 and sUPAR. This does not alter the authors’ adherence to all the policies on sharing data and materials. WHS declares that his institution received research funding for this study. SAM declares research funding from Bluejay Diagnostics, Cytovale and Grifols outside of the submitted work. CJL declares research funding to his institution for the submitted work; grants to his institution from NIH, CDC, DoD, Entegrion, Endpoint Health, Biomeme, AstraZeneca and Novartis outside the submitted work; being Editor-in-Chief of the Journal of Clinical and Translational Science; paid service on DSMBs; consulting to VUMC; stock options in Bioscape Digital; patents for stratification in sepsis and septic shock issued to CCHMC. All the other authors have no conflict of interest to disclose.
: Informed consent was obtained from all individual participants or their legal representative.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the local Independent Review Board of each site.
